Wiregraph

Market coverage built from listed-company disclosures. Email [email protected] for any enquiries.

Copyright © 2025-2026 Wiregraph.com | Market data and charting by TradingView.com

GENMAB

GMAB.CODK0010272202NASDAQ CopenhagenDKDKK
Stock price
GENMAB
Loading chart...

Coverage

Latest articles

Genmab's experimental cancer drug shows encouraging results in endometrial cancer trial
8 Jun 2025, 20:28GMAB.CONASDAQ Copenhagen

Filings

Recent filings

FilingDate
Report Pursuant to Section 28a of the Danish Securities Trading Act10 May 2007
Interim Report 1st Quarter 20078 May 2007
Genmab Announces 2007 First Quarter Results8 May 2007
Articles of Association dated April 19, 20073 May 2007
New Data on Genmab and GlaxoSmithKline's Ofatumumab: Phase II Study in Rheumatoid Arthritis to be Presented at EULAR25 Apr 2007
Genmab to Present at 7th Annual Fortis Bank Biotechnology Conference24 Apr 2007
Passing of Genmab A/S' Annual General Meeting19 Apr 2007
Constitution of the Board of Directors in Genmab and Grant of Warrants to Board Members and Employees
Search

Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.

  • Previous
  • 1
  • 2
  • 3
  • Next
19 Apr 2007
Genmab Initiates HuMax-EGFr Combination Study in Non Small Cell Lung Cancer12 Apr 2007
Genmab's 2006 Annual Report29 Mar 2007
Genmab A/S Summons Annual General Meeting29 Mar 2007
Genmab to Present at Lehman Brothers Tenth Annual Global Healthcare Conference19 Mar 2007
  • Previous
  • 1
  • More pages
  • 120
  • 121
  • 122
  • More pages
  • 156
  • Next
Company
GENMAB
GMAB.CONASDAQ Copenhagen
Website: Unavailable
Coverage
13
Filings
1,863